FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) February 20, 2024 (February 15, 2024)

Merck & Co., Inc.
(Exact name of registrant as specified in its charter)

New Jersey
(State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-1918501 (I.R.S. Employer Identification No.)

126 East Lincoln Avenue, Rahway, NJ 07065 (Address of principal executive offices) (Registrant’s telephone number, including area code) (908) 740-4000

Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

<table>
<thead>
<tr>
<th>Title of each class</th>
<th>Trading Symbol(s)</th>
<th>Name of each exchange on which registered</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock ($0.50 par value)</td>
<td>MRK</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>0.500% Notes due 2024</td>
<td>MRK 24</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>1.875% Notes due 2026</td>
<td>MRK/26</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>2.500% Notes due 2034</td>
<td>MRK/34</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>1.375% Notes due 2036</td>
<td>MRK 36A</td>
<td>New York Stock Exchange</td>
</tr>
</tbody>
</table>
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

(b) On February 15, 2024, Peter C. Wendell gave notice to Merck & Co., Inc. (the “Company”) of his intention to retire from the Board of Directors of the Company (the “Board”) as of the Company’s 2024 Annual Meeting of Shareholders on May 28, 2024. Mr. Wendell’s retirement from the Board is not due to any disagreement with the Company with respect to any matter relating to the Company’s operations, policies or practices.
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Merck & Co., Inc.

Date: February 20, 2024

By: /s/ Kelly E. W. Grez

Kelly E. W. Grez
Corporate Secretary